Emotion recognition in early Parkinsonâ€™s disease patients undergoing deep brain stimulation or dopaminergic therapy: a comparison to healthy participants by Lindsey G. McIntosh et al.
AGING NEUROSCIENCE
ORIGINAL RESEARCH ARTICLE
published: 21 January 2015
doi: 10.3389/fnagi.2014.00349
Emotion recognition in early Parkinson’s disease patients
undergoing deep brain stimulation or dopaminergic
therapy: a comparison to healthy participants
Lindsey G. McIntosh1,2, Sishir Mannava1, Corrie R. Camalier1, Bradley S. Folley3, Aaron Albritton1, Peter E.
Konrad1, David Charles4, Sohee Park2 and Joseph S. Neimat1*
1 Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
2 Department of Psychology, Vanderbilt University, Nashville, TN, USA
3 Norton Neuroscience Institute, Louisville, KY, USA
4 Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA
Edited by:
Tania Álvarez Avellón, Universidad
de Oviedo, Spain
Reviewed by:
Alessandro Stefani, University of
Rome, Italy
Michele Poletti, Azienda Sanitaria
Locale di Reggio Emilia, Italy
Tania Álvarez Avellón, Universidad
de Oviedo, Spain
*Correspondence:
Joseph S. Neimat, Department of
Neurological Surgery, Vanderbilt
University Medical Center, 4340




Parkinson’s disease (PD) is traditionally regarded as a neurodegenerative movement
disorder, however, nigrostriatal dopaminergic degeneration is also thought to disrupt non-
motor loops connecting basal ganglia to areas in frontal cortex involved in cognition and
emotion processing. PD patients are impaired on tests of emotion recognition, but it
is difficult to disentangle this deficit from the more general cognitive dysfunction that
frequently accompanies disease progression. Testing for emotion recognition deficits early
in the disease course, prior to cognitive decline, better assesses the sensitivity of these
non-motor corticobasal ganglia-thalamocortical loops involved in emotion processing to
early degenerative change in basal ganglia circuits. In addition, contrasting this with a group
of healthy aging individuals demonstrates changes in emotion processing specific to the
degeneration of basal ganglia circuitry in PD. Early PD patients (EPD) were recruited from
a randomized clinical trial testing the safety and tolerability of deep brain stimulation (DBS)
of the subthalamic nucleus (STN-DBS) in early-staged PD. EPD patients were previously
randomized to receive optimal drug therapy only (ODT), or drug therapy plus STN-DBS
(ODT + DBS). Matched healthy elderly controls (HEC) and young controls (HYC) also
participated in this study. Participants completed two control tasks and three emotion
recognition tests that varied in stimulus domain. EPD patients were impaired on all emotion
recognition tasks compared to HEC. Neither therapy type (ODT or ODT + DBS) nor therapy
state (ON/OFF) altered emotion recognition performance in this study. Finally, HEC were
impaired on vocal emotion recognition relative to HYC, suggesting a decline related to
healthy aging. This study supports the existence of impaired emotion recognition early in
the PD course, implicating an early disruption of fronto-striatal loops mediating emotional
function.
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INTRODUCTION
While Parkinson’s disease (PD) is traditionally regarded as a
neurodegenerative motor disorder, there is growing evidence for
significant cognitive and emotional impairment, particularly as
the disease progresses (for review see Owen, 2004). Degeneration
of the substantia nigra pars compacta and the subsequent loss
of dopaminergic input to the rest of the basal ganglia affects
cortex through several corticobasal ganglia-thalamocortical cir-
cuits (Alexander et al., 1986). These structurally and function-
ally segregated loops connecting the basal ganglia to cortex are
described as having motor, association (cognitive), or limbic
functions (Alexander and Crutcher, 1990; Middleton and Strick,
2002; Le Jeune et al., 2008). Disruption of associative and limbic
loops is thought to be one factor contributing to the accompa-
nying cognitive decline, including poor executive functioning and
memory, as well as impaired emotion recognition ability in PD
(Owen, 2004).
The ability to recognize and identify emotional cues in others
is a crucial component of human social interaction. Deficits
in emotion recognition have been tied to poor social compe-
tence, interpersonal functioning, and communication, as well as a
reduced quality of life (Ruffman et al., 2008). In regard to PD, as
disease advancement leads to increased dependance on caregivers,
intact emotion recognition is imperative for maintaining these
intimate and essential relationships.
There is a growing literature evidencing impaired facial and
vocal emotion recognition in PD and other diseases of the
basal ganglia, including progressive supranuclear palsy (Gray
and Tickle-Degnen, 2010; Péron et al., 2012; Pontieri et al.,
2012). With respect to PD, neuroimaging work has found this
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impairment to be associated with bilateral orbitofrontal cortex
(OFC) gray matter loss in PD (Ibarretxe-Bilbao et al., 2009).
Importantly, this emotion recognition deficit is separable from
an underlying visuoperceptual and cognitive dysfunction (Gray
and Tickle-Degnen, 2010; Herrera et al., 2011). Deficits in vocal
emotion recognition (i.e., prosody), in contrast, may not be com-
pletely separable from underlying deficits in working memory
and executive function (Gray and Tickle-Degnen, 2010). While
there is support for this remaining deficit for emotion recognition
after factoring out dementia or other gross cognitive impairments
in PD, few studies have investigated emotion recognition ability
earlier in the disease progression.
Patients in the early stage of disease progression (Early PD,
or EPD) are less likely to have developed cognitive impairment
or dementia than their later-staged PD counterparts, as cogni-
tive impairment is positively correlated with neuropathological
staging in PD (Braak et al., 2005). A recent study documented
that 70% of EPD patients showed normal cognitive performance
(Elgh et al., 2009) and what deficits they do have tend to be mild
(Lees and Smith, 1983; Owen, 2004). In contrast, prevalence of
dementia in PD patients surviving past 90 years of age is over
80% (Buter et al., 2008). It is therefore more likely that perfor-
mance of EPD patients on tasks of emotion recognition reflects
the specific integrity of these emotion-related processes. The
literature on emotion recognition in EPD is mixed, with several
studies finding impairment similar to that of later disease stages
(Sprengelmeyer et al., 2003; Dujardin et al., 2004a; Ibarretxe-
Bilbao et al., 2009; Poletti et al., 2013) and others finding it
generally intact (Pell and Leonard, 2005; Péron et al., 2009; Roca
et al., 2010). Likely contributing to these differential findings
is variation in treatment type and medication status across PD
samples studied.
Two effective and common therapies for the motor symp-
toms of PD are dopaminergic medication and deep brain stim-
ulation (DBS) of the subthalamic nucleus (STN). STN-DBS
surgery was first reserved for advanced PD, but now is increas-
ingly considered for those earlier in the disease progression
(deSouza et al., 2013; Schuepbach et al., 2013; Charles et al.,
2014) as it allows for the reduction of dopaminergic medication
(Vingerhoets et al., 2002; Charles et al., 2004). Although both DBS
and dopaminergic medication therapies are effective in controling
motor symptoms of PD, their effects on emotion are not well
understood.
A recent meta-analysis reports that the effect size for PD
emotion recognition impairment to be large regardless of med-
ication state (Gray and Tickle-Degnen, 2010). Two studies testing
affect recognition in early PD samples also found no differ-
ence in task performance between medicated and unmedicated
patients (Péron et al., 2009; Roca et al., 2010). However, many
studies have observed either evidence for beneficial and delete-
rious effects of levodopa on emotion recognition in PD. Diver-
gent findings may be explained by understanding the specific
brain regions supporting the particular emotion task at hand.
For instance, Cools et al. (2001, 2002, 2003) hypothesize that
medication is likely to lead to enhanced performance (relative
to “off ” medication) for tasks involving DLPFC, where DA
loss is significant. However, for tasks engaging OFC or other
more ventral areas of PFC that are relatively unaffected by DA
loss, medication may impair performance through an overdose
action.
The literature is similarly inconclusive on the effects of STN-
DBS on emotion recognition. Several studies have found no
effect of STN stimulation on emotion processing (Schneider
et al., 2003; Péron et al., 2010b; Brück et al., 2011; Albuquerque
et al., 2014). However, others have found specific deficits in
the recognition of fear (Biseul et al., 2005; Drapier et al., 2008;
Péron et al., 2010a), sadness (Dujardin et al., 2004b; Drapier
et al., 2008; Péron et al., 2010a), as well as anger and disgust
(Dujardin et al., 2004b) post-STN-DBS surgery compared to
pre-surgery. Mondillon et al. (2012) discusses possible reasons
for such divergent findings on the effects of medication and
stimulation on emotion recognition, and hypothesizes that STN-
amygdala modulation may correct the levodopa overdose on
OFC. Therefore the best emotion recognition performance may
result from the combination of both levodopa and STN-DBS
therapies. Additionally, methodological differences likely account
for some of the variability in these findings. Interpreting results
from studies comparing pre and post DBS surgery is difficult
because there is often change in medication dose as well as the
effect of invasive nature of the surgical procedure. Therefore, to
understand the effects of stimulation itself, direct comparison of
post-surgery performance with STN stimulation turned “on” and
“off ” is most appropriate.
The aim of this study is to investigate the ability of PD patients
early in the disease course to recognize and identify emotion.
By capitalizing on an ongoing prospective study examining the
safety and tolerability of STN-DBS surgery in early-stage PD
patients, we sought to expand our understanding of the develop-
ment of neuropsychological sequelae of PD and possible effects
of therapy. First, we tested emotion recognition performance
across three stimulus domains (face, voice, face + voice), thereby
increasing the generalizability of our findings to real life emotion
perception. Second, we contrasted the effects of two kinds of
therapy on emotion processing. Specifically, we capitalized on
the randomized nature of the larger study to compare EPD
patients who were randomly assigned to receive optimal drug
therapy (ODT) to those randomly assigned to receive drug ther-
apy plus STN-DBS (ODT + DBS). The washout nature of the
larger study additionally allowed a within-subject approach of
on vs. off either therapy. Third, we utilized two healthy control
groups in order to separate emotion recognition impairments




Demographic information is summarized in Table 1. Sixteen EPD
patients were recruited from the Vanderbilt Clinic of Neurological
Surgery from an ongoing pilot clinical trial testing the safety and
efficacy of DBS therapy in early-stage PD at Vanderbilt University
Medical Center (NCT00282152, IRB 040797, FDA investigational
device exemption G050016) (Charles et al., 2014). Seven of these
patients were recruited from a group of patients randomized
to receive optimal drug therapy only (ODT group), while nine
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Table 1 | Participant clinical and demographic information and performance on control tasks.
Healthy adults Early Parkinson’s disease patients
HYC HEC ODT ODT + DBS
N 21 23 7 9
Sex 12 F, 9 M 10 F, 13 M 2 F, 5 M 1 F, 8 M
Age (years) 20.00 ± 1.87 61.96 ± 7.76 62.29 ± 9.09 62.22 ± 7.97
Education (years) 13.24 ± 1.30 15.13 ± 2.80 15.86 ± 2.73 14.22 ± 2.49
WTAR IQ 110.25 ± 5.89 112.26 ± 11.94 108.29 ± 7.18 108.44 ± 9.81
WASI IQ – 119.30 ± 11.04 111.86 ± 12.58 108.44 ± 16.76
LEDD (mg) – – 551.1 ± 197.2 348.7 ± 240.3
UPDRS ONa – – 21.43 ± 9.88 26.13 ± 14.43
UPDRS OFFb – – 37.57 ± 8.24 36.75 ± 16.99
BFRTc 48.62 ± 2.85 48.18 ± 3.88 42.57 ± 4.16 46.71 ± 3.73
DTTd 94.80 ± 6.22 91.54 ± 9.79 82.42 ± 16.89 89.74 ± 12.16
Mean ± standard deviation (SD) reported where appropriate. aUPDRS motor scores in the ON state (ODT: on medication; ODT+ DBS: on medication and on
stimulation) and bOFF state (ODT: off medication; ODT+ DBS: off medication and off stimulation). cBFRT has a maximum score of 54. dDTT performance presented
as percent accuracy ± SD. EPD patients, DTT scores from ON therapy state are reported.
patients were recruited from a group randomized to receive STN-
DBS surgery in addition to drug therapy (ODT + DBS group).
Prior to completing our tasks, ODT + DBS patients were previ-
ously implanted with bilateral electrodes in the dorsolateral part
of the STN using methods identical to those used in later-stage
patients (Kahn et al., 2012; Camalier et al., 2014). At the time of
testing, DBS stimulation amplitude averaged 1.70 V (±0.31) in
left electrode, and 1.64 V (±0.25) in right electrode. All ODT +
DBS patients had settings of 130 Hz and 60 µs bilaterally. Con-
sistent with study criteria (Charles et al., 2014), all EPD patients
were between the ages of 50 and 75, had a clinical diagnosis of PD,
had not passed Hoehn and Yahr stage II of the disease (Hoehn
and Yahr, 1967), had been treated with levodopa for more than 6
months but less than 4 years, and had not developed on/off motor
fluctuations (for full inclusion criteria see Charles et al., 2014).
Twenty-three healthy elderly control participants (HEC) who
were matched to the EPD patients on age (t(37) =−0.11, p = 0.91),
sex (χ2 = 2.60, p = 0.11), estimated premorbid IQ (t(37) = 1.1,
p = 0.27), and years of education (t(37) = 0.22, p = 0.83), were
recruited from Nashville area. HEC had higher current IQ than
EPD patients (t(37) = 2.27, p = 0.03), but mean current IQ for EPD
patients was still above average. In addition, 21 healthy young
control participants (HYC) were recruited from the Vanderbilt
University student subject pool. HYC and HEC were matched
on estimated premorbid IQ (t(34.00) = 0.70, p = 0.49) and sex
(χ2 = 0.82, p = 0.37). HEC had more years of education than HYC
(t(31.67) =−2.91, p = 0.006), who were still in school.
All procedures were in accordance with the ethical standards
of Vanderbilt University Institutional Review Board and with
the Helsinki Declaration of 1975. Written informed consent was
obtained from all participants after they were given a complete
description of the study. HEC were paid and HYC received course
credit for their participation.
NEUROPSYCHOLOGICAL TESTING
Pre-morbid IQ (e.g., estimated IQ before onset of disease) was
estimated for all participants using the Wechsler Test of Adult
Reading (WTAR; Wechsler, 2001). EPD patients and HEC also
completed the Wechsler Abbreviated Scale of Intelligence (WASI;
Wechsler, 1999) in order to obtain an estimated current IQ. The
difference between estimated premorbid and current IQ was used
to screen for evidence of early dementia (if WTAR > WASI by
more than 1 standard deviation (15 index points) patient would
be excluded). Consistent with the early-stage nature of the disease
in this group, no EPD or HEC participants were excluded from
the present study using these criteria. All testing took place at the
Vanderbilt Neurosurgery Clinic or Vanderbilt Clinical Research
Center.
PROCEDURE
EPD patients underwent 8-day inpatient evaluations at baseline
optimal therapy with a 24-h period of washout from drug ther-
apy and stimulation (see Charles et al., 2014 for full methods
description). EPD patients were tested first in the ON therapy
condition on day 1. In the ON condition, both groups of EPD
patients were receiving optimized doses of medication, ODT
+ DBS patients were also receiving optimum STN stimulation
as set by the clinical trial. After day 1, EPD patients began a
medication washout period. In this study, OFF therapy testing
occurred at least 24-h into the washout period (mean = 2.5
days, sd = 0.73). In the OFF condition, all therapy was dis-
continued (i.e., all patients had discontinued medications and
ODT + DBS patients had also discontinued stimulation). Due
to fixed study design of the larger clinical trial, testing order
of therapeutic state was not counterbalanced and all patients
were tested first in the ON therapy condition, and second in
the OFF therapy condition. Potential effects due to practice are
addressed in Section Discussion. In order to avoid interference
with larger clinical study, we attempted to minimize testing time
for the current study. As such, the entire testing battery was
not completed for some patients. To aid in interpretation of
results, the number of participants for which data was available is
reported by task. Levodopa equivalent daily dose (LEDD) at study
enrollment was calculated using the formula from Tomlinson
et al. (2010). Average LEDD for ODT and ODT + DBS patients
is reported in Table 1. Four patients (2 ODT, 2 ODT + DBS)
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were taking levodopa only, five patients were taking dopamine
agonists only (1 ODT, 4 ODT + DBS) and seven patients were
taking a combination of levodopa and dopamine agonists (4 ODT,
3 ODT + DBS). HEC and HYC participants completed all
testing in one session, approximately 90 min. Unlike the EPD
patients, healthy control participants completed all tasks only
once. HYC completed the WTAR, but not WASI, in order to
reduce testing time, as dementia was not a concern for this
population.
TESTING BATTERY
The battery included three tasks assessing emotion recognition
ability across three stimulus domains: Montreal Affective Voices
Task (MAV, voice; Belin et al., 2008), the Baron-Cohen Reading
the Mind in the Eyes Task (RMET, face; Baron-Cohen et al., 2001),
and the Awareness of Social Inference Test (TASIT, face + voice;
McDonald et al., 2003, 2006). The testing battery also included
two control tasks, the Benton Facial Recognition Test (BFRT;
Benton, 1983) and the Distorted Tunes Test (DTT; Drayna et al.,
2001).
The MAV is a validated set of 90 nonverbal affect bursts cor-
responding to the emotions of anger, disgust, fear, pain, sadness,
surprise, happiness, and pleasure, and neutral. The voices belong
to five male and five female actors, each actor vocalizing the
nine emotions (Belin et al., 2008). After hearing each stimulus,
participants chose between the nine options on the screen. MAV
has been previously used to assess prosodic emotion recognition
in PD (Eitan et al., 2013), progressive supranuclear palsy (Ghosh
et al., 2012) as well as schizophrenia (Alba-Ferrara et al., 2013)
and major depressive disorder (Naranjo et al., 2011). Neuroimag-
ing results show poor MAV performance associated with gray
matter loss in right inferior frontal and left middle frontal gyri
(Ghosh et al., 2012). Electrophysiological evidence also points
to involvement of ventral area of the right STN during this task
(Eitan et al., 2013).
The RMET is a set of 36 black and white images of the eye
region of faces, designed to assess the affective component of
Theory of Mind (Tom; Baron-Cohen et al., 2001). Each stimulus
is presented with four adjective answer choices. Participants are
instructed to choose the word that best describes what the person
in the image is thinking or feeling. Answer choices extend beyond
the Ekman (1972) six emotions generally considered to be uni-
versal, with complex options such as fantasizing, contemplative,
playful, and amused. While not a classic emotion recognition
task, RMET has been previously used to assess affective pro-
cesses in PD (Péron et al., 2009, 2010c; Bodden et al., 2010;
Roca et al., 2010; Poletti et al., 2011; Tsuruya et al., 2011),
autism (Baron-Cohen et al., 2001), and schizophrenia (meta-
analysis: Bora et al., 2009). Posterior superior temporal sulcus
and inferior frontal gyrus are among the cortical areas thought
to support RMET performance (Adams et al., 2010; Moor et al.,
2012).
The TASIT consists of videotaped vignettes of everyday social
interactions designed to assess various components of social per-
ception. TASIT has been used in clinical populations including
traumatic brain injury (TBI; McDonald and Flanagan, 2004;
McDonald and Saunders, 2005; Williams and Wood, 2010),
frontotemporal dementia (Kipps et al., 2009), chronic depres-
sion (Ridout et al., 2007), and schizophrenia (Kern et al., 2009;
Roberts and Penn, 2009). In the current study, we used a
TASIT subtest, the Emotion Evaluation Test (EET), to assess
the recognition of spontaneous emotional expression (happy,
surprised, sad, anxious, angry, disgusted, and neutral). Partici-
pants were shown 28 audiovisual vignettes, with a seven forced-
choice response following the end of each trial. TASIT consists
of forms A and B, which were counterbalanced by testing session
in the EPD groups, and by participant in the HEC and HYC
groups. Impaired emotion recognition performance on TASIT
has been found in patients with nonspecific TBI (McDonald et al.,
2003; McDonald and Flanagan, 2004) as well as those who have
undergone anterior cingulotomies for depression (Ridout et al.,
2007).
The BFRT is a standardized measure with 27 items used to
assess the ability to discriminate and match different faces. It is
often used to screen for lower-level visuoperceptual impairments,
particularly in studies assessing facial affect recognition (Hayes
et al., 2009; Yamada et al., 2009; Hot et al., 2013). Poor perfor-
mance on BFRT has been linked to lesions to right posterior-
inferior parietal and right ventral occipitotemporal cortex (Tranel
et al., 2009). Due to the small sample size we did not use
BFRT as a tool to screen and exclude subjects, but we included
the measure in the testing battery in order to quantify facial
processing ability across the groups. For EPD groups, BFRT
was administered once, during the ON therapy state for each
patient.
The DTT is an auditory processing task with 26 items that
requires participants to judge whether simple popular melodies
contain notes with an incorrect pitch (Drayna et al., 2001; Braun
et al., 2008). Used in other clinical populations as a tool to assess
sensory deficits (Yang et al., 2012), poor performance on DTT is
associated with deficits in processing speech sounds (Jones et al.,
2009). Paired with MAV, DTT allows us to determine whether
impairment in vocal emotion recognition is attributable to lower-
level auditory processing impairment.
All tasks, with the exception of BFRT, were presented on a
computer screen. In order to avoid confounds due to alterations
in motor state, participants provided verbal responses, which were
recorded by experimenter, for all tasks apart from RMET. Due
to verbal response format and instructed emphasis on accuracy,
reaction time was not collected or measured for any task.
DATA ANALYSIS
Mean percent accuracy was calculated for DTT, TASIT, RMET,
and MAV. BFRT was scored out of a possible total long form score
of 54. Statistical tests were performed using SPSS. Due to the small
number of participants in ODT and ODT + DBS groups, for a
subset of the analyses these groups were combined to form one
EPD group for comparison with HEC. HEC performance and
that of EPD patients in the ON condition (first testing condition)
were compared to investigate the effect of PD pathology on
emotion recognition. To elucidate effects of PD therapy type
(ODT/ODT + DBS) as well as state (ON/OFF), ODT and ODT
+ DBS emotion recognition performances were compared using
repeated-measures ANOVA design. HEC and HYC performances
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Table 2 | Task performance in the ON and OFF therapy state for ODT
and ODT + DBS patients.
Task Therapy ODT ODT + DBS
state
N Mean ± SD N Mean ± SD
DTTa ON 7 82.42 ± 16.89 9 89.74 ± 12.16
OFF 7 77.47 ± 13.22 9 89.32 ± 13.43
TASIT ON 6 72.02 ± 7.30b 9 71.43 ± 13.60
OFF 4 74.11 ± 10.26 9 71.03 ± 15.09
RMET ON 6 67.13 ± 6.90 8 63.22 ± 12.93c
OFF 6 70.37 ± 5.46 7 65.62 ± 21.18
MAV ON 7 62.22 ± 8.19 9 59.38 ± 9.38
OFF 7 63.49 ± 6.92 9 59.63 ± 10.57
Means shown are % accuracy ± SD. N = Number of subjects per condition
and task. ap < 0.05 for effect of therapy state. For within-subjects analyses
comparing ON/OFF performance, patients with data available from only one
testing session were not included. For bTASIT, two ODT patients were excluded
from within-subject analysis for this reason and the adjusted mean ± SD for the
remaining four subjects in the ON therapy state is 69.64 ± 6.84, and for cRMET,
one ODT + DBS patient was excluded and the adjusted mean ± SD for the
remaining seven subjects in the ON therapy state is 66.25 ± 10.46.
were compared to isolate effects of typical aging on these tasks.
For comparisons between EPD and HEC, results are reported
with and without controling for group differences in current IQ
(WASI) and BFRT scores.
RESULTS
Clinical and demographic information for all participants is
provided in Table 1.
PERFORMANCE ON CONTROL TASKS: BENTON AND DTT
HEC had higher BFRT scores than ODT (t(27) = 3.28, p = 0.003)
but not DBS (t(27) = 0.88, p = 0.17) patients. Although they
made more errors than HEC, on average ODT patients performed
in the “normal” range on BFRT (score of ≥41; Benton, 1983).
HEC also had higher DTT scores than ODT, though this did not
reach statistical significance (t(25) = 1.75, p = 0.09). HEC and
ODT + DBS patients had very similar DTT scores (t(27) = 0.42,
p = 0.68). Means ± standard deviation (SD) for BFRT and DTT
performance are reported in Table 1.
EFFECT OF PD THERAPY TYPE AND STATE
For each emotion recognition task, a 2 (treatment type: ODT/
ODT + DBS) × 2 (treatment state: ON/OFF) repeated-measures
ANOVA was conducted on the mean percent accuracy. There was
no significant effect of treatment type (p > 0.4 for all tasks) or
treatment state (p > 0.5 for all tasks) on emotion recognition
tasks. There was, however, a significant effect of therapy state on
DTT performance (F(1,14) = 4.82, p = 0.045). This was the result
of ODT performing worse on DTT during OFF state, as ODT +
DBS patients showed no ON/OFF differences in performance. For
the DTT interaction between therapy type and state, there was
a moderate trend toward significance (F(1,14) = 3.41, p = 0.09).
Means and SD for these analyses are reported in Table 2.
EFFECT OF HEALTHY AGING ON EMOTION RECOGNITION
Means ± SD and t-values for emotion recognition tests are
reported in Table 3. HEC and HYC performed similarly overall on
TASIT (t(37) = 0.65, p = 0.52). However, with respect to specific
emotion recognition performance, HEC performed significantly
better than HYC at identifying disgusting videos (t(23.18) =−2.13,
p = 0.04). The opposite was true for neutral videos (t(37) = 2.63,
p = 0.01). There was no effect of age on RMET performance
(t(36) = 0.35, p = 0.73). There is a significant effect of age
on overall MAV performance (t(29.65) = 4.57, p < 0.001), due
to HEC performing worse than HYC. This age-related impair-
ment was evident in specific emotion conditions including anger
(t(34) = 2.98, p = 0.005), fear (t(34) = 4.79, p < 0.001), happy
(t(20.00) = 4.18, p < 0.001), neutral (t(22.79) = 4.26, p < 0.001),
and pain (t(34) = 2.42, p = 0.02).
EFFECT OF EPD PATHOLOGY ON EMOTION RECOGNITION
Because we found no effect of PD therapy type on emotion
recognition performance between the ODT and ODT + DBS
groups, we combined these two groups into one (EPD) so that we
would be better powered to detect group differences on tasks with
HEC. Means ± SD and t-values for HEC and EPD performance
on emotion recognition tests are reported in Table 3.
TASIT (emotion recognition from faces + voices): T-tests
found that EPD patients performed worse than HEC on TASIT
overall (t(33) = 3.70, p = 0.001). Specific affect impairment was
found for disgusted, anxious, and neutral. Statistical trends for
specific affect impairments were found for sad (p = 0.07), happy
(p = 0.06), and surprised (p = 0.05). Group effect remained sig-
nificant after controling for current IQ (F(1,32) = 7.76, p = 0.009).
BFRT performance was found to be unrelated to TASIT accuracy
(F(1,30) = 1.02, p = 0.32).
RMET (emotion recognition from faces): EPD patients also
performed worse than HEC on RMET (t(31) = 2.98, p = 0.006).
This effect remained significant at trend level (F(1,32) = 3.73,
p = 0.06) after controling for current IQ. BFRT performance was
unrelated to RMET accuracy (F(1,27) = 0.04, p = 0.84).
MAV (emotion recognition from voices): T-tests showed EPD
patients performed worse than HEC on MAV (t(35) = 2.02,
p = 0.05). The groups also diverged in performance for angry
(t(35) = 2.57, p = 0.02), and surprised (t(35) = 3.24, p = 0.003) con-
ditions. After controling for current IQ, EPD and HEC performed
similarly overall on MAV (F(1,34) = 0.679, p = 0.42).
DISCUSSION
We found that EPD patients are impaired on emotion recognition
across three types of stimuli relative to matched healthy controls.
Impairment on facial emotion recognition tasks (RMET, TASIT)
was not accounted for by underlying differences in ability to
process basic facial features. EPD patients’ vocal emotion recog-
nition impairment (MAV) was less pronounced, though specific
deficits in processing of angry and surprised voice stimuli were
found. Similar performance on DTT between EPD patients and
healthy aged matched controls indicate this impairment is not
accounted for by differences in low-level pitch perception. These
group effects were differentially affected by controling for current
IQ (WASI), though this potential confound is tempered by the
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Table 3 | Performance for HYC, HEC, and EPD patients on emotion recognition tests TASIT, MAV, and RMET.
HYC vs. HEC HYC HEC EPD HEC vs. EPD
t t
TASIT N 19 20 15
Overall −0.65 86.47 ± 7.95 84.64 ± 9.56 71.67 ± 11.17 3.70∗∗
Neutral −2.63∗ 92.11 ± 11.94 81.25 ± 3.75 56.67 ± 19.97 4.32∗∗
Disgusted 2.13∗ 81.58 ± 26.14 95.00 ± 10.26 81.67 ± 17.59 2.62∗
Anxious −1.05 89.47 ± 15.17 83.75 ± 18.63 66.67 ± 29.48 2.10∗
Angry −1.66 88.16 ± 15.29 80.00 ± 15.39 83.33 ± 24.40 −0.50
Sad 0.77 80.26 ± 17.83 85.00 ± 17.01 73.33 ± 20.00 1.86
Happy −0.37 80.26 ± 17.83 77.50 ± 27.98 60.00 ± 24.64 1.93
Surprised −0.89 93.42 ± 11.31 90.00 ± 12.57 80.00 ± 16.90 2.01
MAV N 15 21 16
Overall −4.57∗∗ 78.37 ± 4.56 66.98 ± 10.06 60.62 ± 8.71 2.02
Neutral −4.26∗∗ 98.67 ± 5.16 76.67 ± 22.88 68.75 ± 25.53 0.99
Disgusted −0.76 82.00 ± 11.46 77.62 ± 19.98 74.38 ± 11.53 0.58
Afraid −4.79∗∗ 66.00 ± 11.83 41.43 ± 17.11 37.50 ± 18.80 0.66
Angry −2.98∗∗ 54.67 ± 19.95 36.67 ± 16.23 23.13 ± 15.37 2.57∗
Sad −1.72 96.00 ± 6.32 90.00 ± 14.14 88.75 ± 10.25 0.30
Pain −2.43∗ 62.67 ± 16.24 47.62 ± 19.72 43.75 ± 18.93 0.60
Happy −3.65∗∗ 100.00 ± 0.00 92.86 ± 7.84 89.38 ± 10.63 1.15
Pleasure −0.39 76.00 ± 23.84 72.86 ± 23.48 73.75 ± 13.60 −0.14
Surprised −0.36 69.33 ± 17.51 67.14 ± 18.75 46.25 ± 20.29 3.24∗∗
RMET N 19 19 14
Overall 0.12 77.98 ± 11.05 76.68 ± 11.69 64.90 ± 10.60 2.98∗∗
Means shown are % accuracy ± SD. *p < 0.05, **p < 0.01.
fact that the EPD patients in this study had an average IQ of 108
and thus had typical cognitive functioning.
Our finding of facial emotion recognition impairment in EPD
replicates that of a meta-analysis showing this impairment in
later stages of PD (Gray and Tickle-Degnen, 2010). Evidence
of brain regions supporting the affect recognition tasks in the
present study partially overlap with known projections from basal
ganglia to frontal cortex via the associative and limbic loops.
Thus, our findings suggest these loops may be dysfunctional
early in the disease process. Our finding of impaired emotion
recognition from eyes (RMET) does conflict with two studies
(Péron et al., 2009; Roca et al., 2010), which have found intact
RMET performance in early PD. One important methodological
difference between these former studies and the current study,
which may account for divergent results, is the other studies’
use of abbreviated version of the RMET, with half the number
of stimuli used in the current study. Most recently, Poletti et al.
(2013), using the same full 36-item RMET used in the current
study, also found impaired performance in EPD patients relative
to matched healthy controls. While the EPD patients included
in this study were also impaired on emotion recognition from
voice stimuli (MAV), the effect was weaker than those for face
stimuli (RMET, TASIT). This is in contrast to a meta-analysis that
found larger effect size for PD emotion recognition impairment
for vocal stimuli compared to that of faces (Gray and Tickle-
Degnen, 2010). It is possible that prosody recognition deterio-
rates over time as PD progresses, but that remains to be tested
longitudinally.
Our results indicate that dopaminergic medication and STN-
DBS do not differentially affect emotion recognition performance
in EPD. Likely playing a part in many studies that contrast these
two therapies is underlying patient clinical and neuropsychologi-
cal differences between the treatment groups. For example, some
PD patients are not willing to undergo surgery for treatment,
or surgery is contraindicated due to other medical concerns.
Furthermore, existing neurocognitive deficits such as impairment
in semantic fluency, or problems with impulse control, affect the
decision to provide surgical intervention and certainly the surgical
target for DBS (e.g., STN v. globus pallidus interna (GPi)). An
important feature of the current study is that EPD patients were
assigned to their treatment groups through a completely random-
ized process. Perhaps, then, these patient characteristics that often
clinically influence a therapy choice are not a factor for this study
and our results reflect this.
We do not see an effect of STN stimulation on emotion
recognition in this sample. This finding is in contrast to pre-
vious findings that STN-DBS surgery leads to deficits in emo-
tion recognition, particularly for negative emotions (Dujardin
et al., 2004b; Drapier et al., 2008; Péron et al., 2010a). However,
methodological differences between previous studies and ours
are of note. In this study, patients receiving STN stimulation
(ODT + DBS) were of early PD progression, not past Hoehn and
Yahr stage II. Additionally, this study isolates the effect of STN-
DBS stimulation from that of DBS surgery, which may confer
its own effects on emotion recognition processes (Brück et al.,
2011) as well as executive function (Okun et al., 2009). There is
extremely limited evidence for the effect of STN-DBS stimulation
in early PD, and for this reason it is very difficult to compare our
finding to the published literature on STN stimulation effects.
In comparison to published studies examining STN stimulation
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in advanced PD patients, stimulation levels in this study (ODT
+ DBS group) were relatively low; under 2 V. It is possible that
this low setting is efficacious for controling motor symptoms
but does not exert measurable extra-motor side effects. Another
possibility is potential disruptive effects of stimulation, exhibited
in the other studies, is only evidenced as disease progression
itself produces greater deficits in emotional processing. In view
of the concerns for cognitive change associated with STN-DBS
in advanced PD, this study seems to indicate that STN-DBS,
when applied early in the therapy, does not worsen the pre-
existing decline in emotional processing already present early in
the disease.
A similar lack of ON/OFF effect for emotion recognition
was found on dopaminergic medication therapy in the ODT
group. The literature on the effect of dopaminergic medication
on emotion processing in PD (most of which has been conducted
in moderate to severe PD populations) is mixed. It is possible that
early in the disease progression, levodopa or dopamine agonists
do little to affect emotion recognition processes. Within the EPD
literature, our finding that emotion recognition is unaffected by
medication status is in accordance with other studies (Péron et al.,
2009; Roca et al., 2010). Separate from the emotion recognition
battery used in this study, the DTT did reveal an effect of therapy
state, potentially an effect of medication. DTT was employed
in this study as a perceptual control task, not expected to be
affected by treatment state. This finding certainly requires further
investigation.
Our finding of EPD impairment on tests of emotion recog-
nition is consistent with previous work documenting altered
structure and function of OFC and amygdala in early dis-
ease stages. Ouchi et al. (1999) observed reduced density of
dopamine transporter binding sites in OFC and amygdala in
levodopa naïve, early PD patients. Consistent with progression
of Lewy-body pathology to neocortex (Braak et al., 2003), OFC
(Ibarretxe-Bilbao et al., 2009; Tinaz et al., 2011) and amyg-
dala (Ibarretxe-Bilbao et al., 2009) volumes are decreased by
Hoehn and Yahr stage II. OFC volume is strongly correlated with
emotion recognition performance in EPD patients (Ibarretxe-
Bilbao et al., 2009). However, functional MRI study has sug-
gested that abnormal amygdala activation during perception of
emotional faces is present in EPD prior to manifestation of
behavioral impairment in emotion recognition (Tessitore et al.,
2002).
It is important to consider how neuropsychological assess-
ments for emotion recognition or discrimination abilities may
be included in neuropsychological assessments for PD. Early
detection of an emotion recognition deficit could direct the
patient to interventions, for instance, social cognition training, to
remediate the impairment before it worsens. While not yet studied
in PD, such interventions are found to be effective in improving
social cognition in disorders such as schizophrenia (Horan et al.,
2008; Roberts and Penn, 2009) and autism (Turner-Brown et al.,
2008). Emotion recognition tests employed in research could be
easily adapted for neuropsychological assessment, assuming suf-
ficient normative data exists. For example, Ekman and Friesen’s
(1975) classical facial affect recognition test is now a subtest
in the Social Cognition and Emotional Battery (SEA; Bertoux
et al., 2012; Funkiewiez et al., 2012), used for early diagnosis
of the behavioral variant of frontotemporal dementia (bvFTD),
where aberrant social behavior is often the presenting symptom.
The RMET (Baron-Cohen et al., 2001) is already widely used
in research for assessing ToM in different clinical populations.
While there is some normative data available (Baron-Cohen
et al., 2001), we know little about how healthy older adults
perform on this task, preventing present adoption of the task
in neuropsychological assessment of the elderly. Although not
greatly impaired in this EPD sample, deficits in vocal emotion
recognition are more striking than for facial emotion recognition
in later stages of PD (Gray and Tickle-Degnen, 2010). To our
knowledge, no neuropsychological testing includes vocal emotion
recognition tests. However, the Montreal Affective Voices Battery
(Belin et al., 2008) could be standardized and eventually included
alongside tests of facial affect recognition in neuropsychological
assessments.
Finally, it is still relatively unknown how deficits on tests
of emotion recognition translate into patients’ every day social
behaviors, so future research should endeavor to link test
performance with a real-life measure of social functioning.
Additionally, the development of more ecologically valid mea-
surements of social cognition, such as gaze behavior, is war-
ranted (Sturm et al., 2011; see also Kumfor and Piguet,
2013).
EFFECT OF AGING ON EMOTION RECOGNITION
By including two healthy control groups in this study, we were
able to capture effects of typical aging on emotion recognition.
Our finding of a robust HEC impairment on MAV, relative to
HYC, indicates that decoding of emotional prosody deteriorates
with age. This is in accordance with previous studies investigating
the affect of aging (Ruffman et al., 2008; Mill et al., 2009),
reporting deficits in vocal emotion processing in older adults.
Importantly, there was no difference between HYC and HEC
in performance on DTT, our auditory control task. This sug-
gests that the finding cannot be attributed to age-related hearing
loss, which is also in line with previous research (Orbelo et al.,
2005; Mitchell, 2007). However, other studies (Mill et al., 2009;
Ruffman et al., 2008, 2009) have also reported that facial affect
recognition also deteriorates with age, particularly that of negative
emotions. This HEC sample performed similarly to HYC on our
facial emotion recognition tasks, TASIT and RMET, with the
exception of neutral and revolted videos in the TASIT. However,
most previous studies investigating facial affect recognition use
static face stimuli, different from that used in the current study.
TASIT requires the integration of contextual verbal and non-
verbal information from social interaction. RMET provides only
the eye region of faces, so perhaps it is easier focusing on only this
region, though studies have observed aging related impairment
on this task as well (see Kemp et al., 2012 for review). Addition-
ally, the answer choices for RMET are dissimilar to those used
in typical affect recognition tasks, as it was originally designed
to assess affective ToM. It is possible that these methodolog-
ical differences could account for the differences between our
study and previous studies investigating the effects of healthy
aging.
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LIMITATIONS
It is important to note certain limitations to our study. Due to
study constraints, we were unable to counterbalance the ther-
apeutic state of the testing sessions in the EPD patients; ON
testing was always first and OFF testing always second. This
limitation is shared by many studies investigating the effect of
STN-DBS on emotion recognition, as a pre vs. post surgery
approach is frequently employed to investigate effects of stim-
ulation. Future studies investigating the effect of PD therapy
on emotion recognition using a similar within-subject design
would ideally counterbalance testing sessions. We were unable
to compare all possible therapy states for EPD-DBS group (e.g.,
DBS-ON/ MED-ON, DBS-ON/MED-OFF, DBS-OFF/MED-ON,
DBS-OFF/MED-OFF). Our ability to compare all possible testing
states was limited by concerns for EPD patients’ comfort and
desire to minimize potential practice effects. Future studies should
compare all possible testing states in order to completely separate
stimulation from medication effects in PD-DBS patients. Addi-
tionally, as this study was initiated after the larger clinical trial
was initiated, pre-surgical testing of emotion recognition was not
possible. Furthermore, EPD patients were not blinded to therapy
state, making placebo effects a possible confound in our results.
Finally, our EPD sample is small, which may have hindered our
ability to detect group differences in such a heterogeneous disease.
As such, the study may have been underpowered to detect effects
of therapy type and state on emotion recognition. Unfortunately,
given the constraints of the larger clinical trial, a larger group of
EPD patents could not be sampled. Interpretation of these results
would benefit from replication in a larger sample.
GENERAL CONCLUSIONS
This study finds emotion recognition impairment in early PD.
This impairment was strongest for tasks of facial affect recogni-
tion. These deficits are not accounted for by lower-level impair-
ment in visual or auditory processing. It is interesting to find such
deficits in patients who otherwise exhibited a normal cognitive
profile. It suggests that alterations of the basal ganglia circuitry
effects both motor and limbic domains before broader cognitive
effects are observed in later PD (Braak et al., 2005). We found
no difference treatment type (ODT/ODT + DBS) on emotion
recognition performance in this early PD sample. The patients
who participated this study were randomized to treatment groups
as part of a larger study, which allowed us to test early PD patients
receiving DBS stimulation; a rare population. This randomized
design also avoids many confounds in patient characteristics that
may otherwise have affected task performance, such as neu-
rocognitive deficits or problems in impulse control. Nevertheless,
this finding would benefit from replication in a larger sample.
By utilizing two healthy control groups (young and elderly),
we were able to replicate the finding that emotional prosody
identification decays with age, and provide evidence that facial
affect recognition remains intact in individuals in their 60 s. Our
results support the existence of altered functioning in non-motor
corticobasal loops early in the PD progression, which is likely
associated with documented disturbances in OFC and amygdala
in EPD patients. Early deficits in the ability to interpret social cues
seen in this study are especially concerning as progressive motoric
impairment in PD often leads to increased reliance on caregivers.
Researchers and clinicians in this field should work toward the
inclusion of emotion perception tests into neuropsychological
assessments to aid in identifying patients who are significantly
impaired in this domain. Provision of education and support
surrounding these interpersonal deficits as a symptom of the
disease may be warranted in an effort to preserve important
relationships with loved ones. Whether these deficits could be
improved through intervention is a critical area that is yet to be
explored in PD.
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